Re-induction with modified CLAG regimen in relapsed or refractory acute myeloid leukemia in children bridging to allogeneic hematopoietic stem cell transplantation

被引:0
作者
Na Zhang
Jing-Bo Shao
Hong Li
Jing-Wei Yang
Kai Chen
Jia-Shi Zhu
Hui Jiang
机构
[1] Shanghai Children’s Hospital,Department of Hematology and Oncology
[2] Shanghai Jiao Tong University,undefined
来源
World Journal of Pediatrics | 2020年 / 16卷
关键词
Acute myeloid leukemia; Children; Cladribine; Refractory; Relapsed;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:152 / 158
页数:6
相关论文
共 198 条
[1]  
Creutzig U(2012)Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel Blood 120 3187-3205
[2]  
van den Heuvel-Eibrink MM(2013)Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia Blood 122 170-178
[3]  
Gibson B(2017)Current management of childhood acute myeloid leukemia Paediatr Drugs 19 1-10
[4]  
Dworzak MN(2017)Improved outcome of childhood acute myeloid leukemia in an Eastern European country: lithuanian experience Eur J Pediatr 176 1329-1337
[5]  
Adachi S(2014)Cladribine in the treatment of acute myeloid leukemia Leuk Res 38 425-427
[6]  
de Bont E(1996)Clinical and laboratory studies of 2-chlorodeoxyadenosine +/− cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults Leukemia 10 1563-1569
[7]  
Pession A(2003)Purine nucleoside analogues in the treatment of myeloid leukemias Leuk Lymphoma 44 391-409
[8]  
Masetti R(1996)Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule Clin Cancer Res 2 653-658
[9]  
Rizzari C(1994)Use of G-CSF before, during and after fludarabine plus Cytarabine induction therapy of newly diagnosed AML or MDS: comparison with fludarabine plus Cytarabine without G-CSF J Clin Oncol 14 671-678
[10]  
Putti MC(1996)Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions Blood 87 256-264